Loading...
•
Dec 31, 2024
Evolent Health Q4 2024 Earnings Report
Evolent Health reported its financial results for the fourth quarter and full year ended December 31, 2024.
Key Takeaways
Evolent Health delivered fourth quarter and full-year results within outlook, despite elevated oncology costs. The company achieved 100% retention across top customers, representing over 90% of 2024 revenue, and announced two new revenue agreements.
Revenue for Q4 2024 was $646.5 million, an increase of 16.3% compared to Q4 2023.
Net loss attributable to common shareholders was $30.6 million for Q4 2024, with a net loss margin of (4.7)%.
Adjusted EBITDA reached $22.6 million in Q4 2024, resulting in an Adjusted EBITDA margin of 3.5%.
The company signed contract amendments expected to yield $115 million annual improvement for 2025.
Evolent Health
Evolent Health
Forward Guidance
For the first quarter of 2025, Evolent expects revenue to be between $440 million and $470 million, with Adjusted EBITDA projected to be between $31 million and $37 million. For the full year 2025, revenue is expected to be between $2.06 billion and $2.11 billion, with Adjusted EBITDA between $135 million and $165 million.
Positive Outlook
- Expected annual growth of 15%-18% in revenue for 2025 after adjusting for one-time contract changes.
- Anticipated $115 million annual improvement for 2025 from contract amendments.
- Continued strong partner contract retention.
- Focus on managing healthcare affordability and enabling quality care.
- Deployment of approximately $35 million in cash for capitalized software development during 2025.
Challenges Ahead
- Continued elevated oncology costs during the quarter.
- Future period non-GAAP guidance includes adjustments for items not indicative of core operations.
- Potential impact of changes to business due to acquisitions and other events.
- Uncertainty regarding future period non-GAAP adjustments due to ongoing assumptions and unanticipated charges.
- Risks associated with the significant portion of revenue derived from largest partners and potential loss or renegotiation of contracts.